
Our review shows that, compared to placebo, the biologics infliximab, bimekizumab, ixekizumab, and risankizumab were the most effective treatments for achieving PASI 90 in people with moderate‐to‐severe psoriasis on the basis of high‐certainty evidence.
Like
Save
Share